The expression rate of SHP2 is high and closely correlated to lymphnode metastasis in NSCLC, which implies the occurrence and development of lung cancer maybe related to SHP2, and SHP2 maybe a new marker and therapeutic targets for lung cancer.

The enhancement of SHP2 expression in non-small cell lung cancer is correlated with tobacco smoking.

Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations.

higher positive rates of expression in non-small cell lung cancer patients with lymph node metastases

SHP-2 is a key signalling node downstream of the DDR2 receptor in lung cancer.

SHP2E76K mutant promotes lung tumorigenesis.

Results show that inhibition of the Shp2 PTP activity impairs mutant EGFR signaling and suppresses EGFRL858R-driven lung adenocarcinoma.

a decrease in PTEN facilitates ROS/SHP2 signaling, causing lung cancer cells to become unresponsive to IFN-gamma

Findings revealed that SHP2 is associated with cisplatin-induced drug resistance in lung cancer and directly activates Ras, which in turn regulates the PI3K/Akt pathway.

SHP2 inhibition is an unexpected vulnerability of KRAS-mutant non-small-cell lung cancer cells.

Results found that SHP2 was highly expressed in EGFR-mutation positive non-small cell lung cancer and an independent factor for poor prognosis for the progression-free survival of the patients.

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling pathway in Non-Small Cell lung cancer.